InMed Pharmaceuticals Inc. (INM)
| Market Cap | 3.44M +17.6% |
| Revenue (ttm) | 4.51M -6.7% |
| Net Income | -7.66M |
| EPS | -2.92 |
| Shares Out | 4.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 41,044 |
| Open | 0.7810 |
| Previous Close | 0.7621 |
| Day's Range | 0.7500 - 0.7810 |
| 52-Week Range | 0.5750 - 7.9800 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 11, 2026 |
About INM
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids ... [Read more]
Financial Performance
In fiscal year 2025, InMed Pharmaceuticals's revenue was $4.94 million, an increase of 7.50% compared to the previous year's $4.60 million. Losses were -$8.16 million, 6.34% more than in 2024.
Financial StatementsNews
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifyin...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimen...
InMed Pharmaceuticals Transcript: Sidoti March Small-Cap Virtual Conference
Lead drug INM-901 showed strong preclinical efficacy in Alzheimer's models, reducing neuroinflammation and improving cognition, with a pre-IND FDA meeting planned for Q3 and clinical trials targeted f...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities Targeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027 Vanc...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline
Vancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of diseas...
InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing...
InMed Announces Results of 2025 Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed Provides Update on BayMedica Commercial Business
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025
The presentation highlighted progress on proprietary drug candidates targeting neuroinflammation and neuroprotection for Alzheimer's and dry AMD, with INM-901 prioritized for its promising preclinical...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vanc...
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing ...
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of prop...
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update
Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-rel...
InMed Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025
Three drug candidates are advancing, with INM-901 for Alzheimer's and INM-089 for dry AMD showing promising preclinical results and moving toward FDA pre-IND meetings next year. The commercial arm rem...
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025
VANCOUVER, British Columbia, Sept. 16, 2025 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of propri...
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
InMed Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Presentations highlighted a robust pipeline targeting Alzheimer's, dry AMD, and dermatology, with INM-901 showing promising preclinical results. Profitable commercial operations support R&D, and strat...
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025
Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity Vancouver, British Columbia--(Newsfile Corp. - July 28, 2025) - InMed Pharmaceuticals Inc....
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro Significantly reduces levels of inflammasome marker, NLRP3, a key contributor to...
InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of propri...
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprie...
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...